Skip to main content
CDC Website

HIV

What is Harm Reduction?

This video is part of the NIDA series At the Intersection: Stories of Research, Compassion, and HIV Services for People who Use Drugs.“Harm reduction” is defined as interventions aimed to help people avoid the negative effects of drug use by meeting people where they are with kindness and respect. In this video, viewers hear from people who use drugs, people who are in recovery from drug use, and harm reduction professionals on what harm reduction is (and isn’t) in their own words.

Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support applications for epidemiological and observational research projects on the long-term cardiopulmonary sequelae following treatment for tuberculosis (TB). Investigators should propose additional testing and data collection in existing cohorts of adult and/or pediatric TB participants to better characterize and understand adverse outcomes and morbidity associated with TB disease post treatment in individuals with and without HIV infection.

NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)

The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative.

TelePrEP Online Learning Series

This TelePrEP Online Learning Series provides information and resources to health departments, community-based organizations, and community health centers wanting to expand, strengthen, or develop a telePrEP program. 

HIV Data Protection Landscape For EHE Jurisdictions

The map summarizes state laws and regulations that addresses authorities and protections related to the health departments HIV surveillance data release, which is in response to data requests from courts, prosecutors, and law enforcement agencies. It also reflects laws in Priority Jurisdictions included in Phase I of the federal “Ending the HIV Epidemic: Plan for America” (EHE) initiative, which aims to end the HIV epidemic in the United States by 2030.

Positive Learning Toolkit

This toolkit aims to address the daily realities of adolescents and young people living with HIV while they are navigating issues, as well as supporting national education sectors to fulfil the needs and rights of all learners living with and are affected by HIV. 

Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional)

Avenir means future in French, and the Avenir Award Program for Research on Substance Abuse and HIV/AIDS looks toward the future by supporting early stage investigators (ESI) proposing highly innovative studies that address NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support creative individuals who wish to pursue innovative research at the nexus of substance abuse and HIV/AIDS.

Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites grant applications aimed at elucidating neuroimmune and neuronal-glial pathophysiological mechanisms of HIV-associated neurological disorders (HAND) using ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the presence of addictive substances. Specific emphasis is on unbiased, reproducible analysis of genetics and epigenetics, neuroglial interactions, and neuroimmune cell activities from the single cell to neural circuit levels